Background: Chlorotoxin is a small scorpion peptide that inhibits glioma cell
Introduction
Chlorotoxin (CTX) is a 36-amino acid peptide found in the venom of the giant Israeli scorpion Leiurus quinquestriatus [1] , which possesses therapeutically interesting bioactivities [2, 3] . CTX displays high binding selectivity for glioma cells and also for cells from other tumours of neuroectodermal origin but not to healthy mammalian cells [2, 4] . This specific activity was initially thought to involve chloride channels expressed on the surface of cancer cell types [5] but recently, matrix metalloproteinase-2 and annexin A2 have been proposed as other possible targets of CTX [6, 7] . CTX also displays anti-angiogenic activity, as demonstrated in in vitro and in vivo bioassays [3] . For example, CTX inhibits the migration of human umbilical vein endothelial cells (HUVECs) in a dose-dependent fashion and inhibits the growth of blood vessels in a chick chorioallantoic membrane (CAM) assay [3] .
The biological activities of CTX have led to several promising applications in cancer treatment or detection [8] [9] [10] [11] [12] [13] [14] . The synthetic version of CTX (TM-601) conjugated to a fluorophore, such as Cy5.5 or IRDye 800CW, retains its tumour binding properties and is being developed as an imaging agent to help distinguish cancerous from noncancerous cells during surgical resection of tumours [9, 10] . A radio-labelled analogue of CTX, 131 I-CTX, has been used as a radiotherapy agent to control and detect tumour progression [11, 12] . In a phase I clinical trial, a single-dose study
showed that 131 I-CTX was well-tolerated by all individuals tested and displayed an encouraging safety profile with no grade 3 or 4 toxicities observed, and was eliminated from the body within 24 to 48 h [12] . 131 I-CTX is currently in phase II clinical trials [12] . CTX has also been used as a targeting signal to deliver drugs to cancer cells [13, 14] , adding to the growing number of applications of CTX in cancer drug development.
Because of its small size and proteinaceous nature, CTX is well suited to modern chemistry methods designed to enhance its therapeutic potential. In a recent study, CTX was modified to produce an optimal peptide for bio-conjugation to Cy5.5 for tumour imaging [15] . The native sequence of CTX, which is shown in Figure 1A , has three lysine residues, leading to a heterogenous mixture of mono-, di-, and tri-labelled peptides after Cy5.5 conjugation, which is an undesirable characteristic for regulatory approval. Thus, CTX was chemically re-engineered to contain only a single lysine at position 27, which was used to produce a mono-labelled molecule able to be used in clinical trials [15] . CTX has also been engineered to have improved stability against serum peptidases. A seven amino acid linker was introduced to connect the N-and Ctermini of the peptide to produce a backbone cyclised analogue, which showed improved serum stability by around 20% compared to that of the native peptide. The cyclic analogue also maintained a similar overall tertiary fold and the ability to bind malignant tissue [15] .
Attempts to re-engineer CTX can be guided by structural information. CTX adopts a well-structured tertiary fold, with four disulfide bonds at the protein core ( Figure 1B) surrounded by an α-helix and three anti-parallel β-strands [16] . Three of the disulfide bonds, Cys II-VI, Cys III-VII and Cys V-VIII, are involved in linking the α-helix to the β-strands, and the fourth disulfide bond, Cys I-IV, connects the N-terminal region with the remainder of the peptide. This structure is similar to that found in members of a scorpion peptide family characterised by an α/β motif and three disulfide bonds [16] . As shown in Figure 2A , comparison of CTX with iberotoxin, a member of the α/β scorpion peptide family, shows that the connectivity of three disulfide bonds are similar, with the additional fourth disulfide bond of CTX, Cys I-IV, being the distinguishing structural feature.
The disulfide bond configuration of CTX incorporates a cystine knot motif. This motif is present in a number of peptide families, including the cyclotides, which are plant-derived cyclic peptides that have emerged as ultra-stable scaffolds in drug design [17] [18] [19] due to a combination of their cystine knot and head-to-tail cyclic backbone. In the cyclotide family, the cystine knot is composed of a topological ring formed by Cys I-IV and Cys II-V and their intervening backbone sequences, through which Cys III-VI penetrates, forming a stable and rigid configuration. In CTX, of the four disulfide bonds, Cys I-IV, Cys II-VI and Cys III-VII are involved in forming the knot and Cys V-VIII can be regarded as an 'extra' crosslink ( Figure 2B ). From this discussion it is clear that CTX is an interesting disulfide-bonded peptide that shares common features with diverse examples of plant and animal toxins and hence it is of interest to examine the role of its individual disulfide bonds in defining structure and activity.
Studies on disulfide bonds in proteins and peptides have revealed that they can have a number of roles in structure, stability and activity, and their modification can be useful for modulating the pharmacological properties of peptides [20] . For the cyclotides, the disulfide bonds contribute to the stability of naturally-occurring examples, as well as to engineered drug leads based on the cyclotide framework [21] [22] [23] . For the α/β scorpion family members, leiurotoxin I and charybdotoxin, specific disulfide bonds are critical for maintaining the native-like structure [24, 25] .
In this study our aim was to determine the role of each of the four disulfide bonds in CTX and delineate their importance to the structure, stability and activity of the peptide. We reasoned that this information might facilitate the use of CTX as a drug design scaffold. We sequentially replaced each disulfide bond with a pair of L-α-aminobutyric acid (Abu) residues and also synthesised an analogue with all disulfide bonds replaced. Herein we report the structural and functional characterisation of these analogues.
Experimental procedures

Synthesis and purification
CTX and the analogues were synthesised on a Symphony Multiplex automated synthesiser using Fmoc solid phase peptide synthesis (SPPS) chemistry. Rink amide resin was used for all synthesis. The Fmoc protecting group was removed using 30% piperidine in DMF, and a 4-fold excess of amino acid was used for coupling of amino using a separation funnel. The crude peptide from this extraction was lyophilised overnight and followed by RP-HPLC purification using C18 columns with 1% min -1 or 0.5% min -1 gradient from 0-60% buffer B and the eluant was monitored at 215 and 280 nm. Purity of peptides was confirmed by LC-MS and analytical RP-HPLC.
Folding and purification
Reduced peptides at 0.1 mg/mL were oxidised in a buffer containing 0.1 M Tris-HCl from 0-60% buffer B was used, and the eluant was monitored at 215 and 280 nm.
Purity of peptides was confirmed by LC-MS and analytical RP-HPLC.
Conformational analysis
The peptides were prepared at 50 µM in 2 mM Tris HCl buffer at pH 7.4 for CD analysis. Spectra were recorded at room temperature with a 0.1 cm path length quartz cell by accumulating three scans, from 180 to 250 nm using a CD spectropolarimeter (Jasco J-810). for an hour. A second alkylation was performed by adding 25 mM iodoacetamide (IAM) and incubating for 30 min at room temperature. Sequencing grade trypsin was added to selected peptides at 1:20 (w/w) ratio in 100 mM ammonium bicarbonate buffer pH 8.0 and digestion was allowed to proceed overnight at 37°C. The samples were desalted using Ziptips (Millipore, C18) prior to analysis.
Reduction and alkylation of disulfide bonds
Sequence determination
ESI-MS analysis was conducted for the digested and undigested peptides. The ESI-MS measurements were performed on a QStar Pulsar I QqTOF mass spectrometer (AB/Sciex, Framingham, USA) equipped with an ESI source in positive ion mode.
The spray voltage was set to 900 V. Nitrogen was used as the collision gas and the collision energies were adjusted manually in the range from 5 to 50 V. After the precursor ion for MS/MS was selected, the MS/MS spectra were collected and recorded for up to 30 min. Recorded mass spectra were analysed with the Analyst QS 2.0 (AB/Sciex) software and the peptide sequenced using b-and y-ions (N-and Cterminal) as described previously [26] .
Serum-stability assay
The stability of native CTX and its analogues was determined as described previously [27, 28] . The incubation time points for all peptides with human serum were 0, 1, 2, 3, 6, 12 and 24 h at 37°C.
Cytotoxicity assay
The cytotoxicity of native CTX and its analogues was performed and analysed as described previously [23] . Briefly, 5x10 3 HUVECs/well were seeded in a 96-well flatbottomed plate in a final volume of 100 µL in 10% FBS/EBM-2 media with supplements (Lonza) and incubated in 5% CO2 overnight at 37°C. Then, the media was removed and 90 µL of fresh media without serum was added to each well. 10 µL of CTX and its analogues were added in triplicates to a final concentrations ranging from 0.1 to 200 µM. 0.1% Triton X-100 was used as a positive control. After incubation for another 2 h, 10 µL of MTT (Sigma) solution in PBS (5 mg/mL) was added to each well and incubated for 3 h. Media was removed, and formazan crystals were resuspended in 100 µL of DMSO. After 10 min the absorbance was read at 600 nm with BioTek PowerWave XS machine.
Migration assay
The in vitro cell migration assay provides measurable antiangiogenic activity of molecules. To determine the activity of native CTX and its analogues, the peptides 
Results
Synthesis, Folding and Purification
The sequences of CTX and the five disulfide bond analogues used in this study, as well as their predicted disulfide bond connectivities are shown in Figure 3 . In CTX1, all cysteine residues were replaced with Abu, whereas for the remaining peptides, only one pair of cysteine residues was replaced. Abu was chosen to be the cysteine substitute because it is isosteric to cysteine but is unable to form a disulfide bond. All peptides were synthesised using solid-phase Fmoc chemistry and yielded reduced peptides that were purified using RP-HPLC and showed a defined peak on analytical
HPLC (Figure 4, black traces).
To examine the effect of the disulfide bonds on the oxidative folding of CTX, the reduced peptides were oxidised at a concentration of 0.1 mg/mL in folding buffer (0.1 M Tris-HCl pH 7.8, 0.2 M NaCl, 5 mM reduced glutathione and 0.5 mM oxidised glutathione), which was the same in composition as that used previously to chemically produce native-like CTX [15] . The addition of organic solvent or detergents has been reported to improve the oxidative yield of disulfide-rich cyclotides [29] . The peptides were therefore also oxidised in folding buffer containing 10% (v/v) DMSO or 15% (v/v) isopropanol to explore the effect of additives on the folding of CTX. The ratio of oxidised (GSSG)/reduced (GSH) glutathione in the folding buffer was kept constant because this ratio has previously been used to obtain the native disulfide bond connectivity for CTX [15] and two related toxins [24, 25] .
The folding mixtures were analysed using analytical HPLC to characterise the yield of the oxidised peptides bearing the native-like disulfide bond connectivity. As illustrated in Figures 4A and 4F , oxidation of reduced CTX resulted in a defined early-eluting peak that corresponded to a folded molecule with the correct disulfide bond connectivity, and this was confirmed by a proton chemical shift analysis using NMR (data not shown). The correctly folded CTX had an earlier elution time than its reduced form, consistent with the correct disulfide bond connectivity promoting the greater exposure of hydrophilic and polar residues. This result was found to be a general phenomenon, with the presence of an early-eluting peak being an indicator of a native-like structure having been formed. The area of the early-eluting peak formed after oxidation of CTX in the folding buffer, the folding buffer plus 10% (v/v) DMSO, and the folding buffer plus 15% (v/v) isopropanol was measured to be 60%, 80% and 100%, respectively. The improved yield of the native-like peptide with the addition of DMSO or isopropanol suggests that organic solvents may encourage the exposure of some hydrophobic residues of CTX, thereby facilitating the formation of the correct disulfide bond connectivity.
Oxidation of reduced CTX2 and CTX3 also produced a defined early-eluting peak in the folding buffer but the intensity of the peak was lower than that obtained for CTX in the same buffer. The area of the peak formed for CTX2 and CTX3, after oxidation, corresponded to 40% and 30%, respectively, compared to that of the corresponding reduced peptide, indicating that the folding process was affected by the removal of the associated disulfide bond (Figures 4B and 4C) . Similar to what was observed for CTX, the presence of 10% (v/v) DMSO or 15% (v/v) isopropanol resulted in an improved yield of the early-eluting peak (Figures 4G and 4H ). The area of the peak formed for CTX2 and CTX3, after oxidation, increased to 60% and 40%, respectively, in the presence of DMSO, and to approximately 60% and 80%, respectively, in the presence of isopropanol. CTX4 did not form a distinctive and high yielding early-eluting peak, suggesting that non-native-like structures were favoured during folding ( Figure 4D ). Similar results were obtained for CTX5 in the folding buffer ( Figure 4E) , and for CTX4 and CTX5 in the folding buffer with 10% (v/v) DMSO or 15% (v/v) isopropanol (Figures 4I and 4J ).
Oxidised peptides were purified and their masses determined using mass spectrometry. The observed masses were consistent with the calculated masses of CTX and its analogues, which were 3993.6 Da and 3959.6 Da, respectively, confirming that the correct number of disulfide bonds had formed. After the oxidation of CTX3 in the presence of DMSO, an additional early-eluting peak with a mass of 4572.2 Da was observed ( Figure 4H , marked with an asterisk), which probably represents CTX3 attached to two glutathione molecules (MW = 612.6 Da). Covalent linkage of glutathione during oxidation was previously reported for charybdotoxin [25] . A mass spectrometry analysis of the chromatogram of the oxidation of CTX4
and CTX5 identified the presence of an oxidised peptide mass at several different retention times, suggesting that multiple non-native-like disulfide bond connectivities had formed. CTX analogues contain six cysteine residues that can adopt 15 different oxidised disulfide species. The presence of multiple peaks during the folding process suggests that the native-like peptide is not the most favoured end product. Since the oxidation trials indicated that CTX4 and CTX5 did not efficiently oxidise into the native-like fold, we focussed on CTX2 and CTX3 in the subsequent conformational and stability studies.
Conformational analysis
Circular dichroism (CD) spectra for proteins or peptides have particular signatures that reflect the secondary structure [30] . As shown in Figure 5 , the CD spectrum of CTX showed both a positive maximum at around 190 nm and two negative minima at approximately 209 nm and 220 nm, indicating the presence of an α-helical secondary structure element. This result is consistent with the three dimensional structure of CTX where there is an α-helix spanning residues 12 to 19 (Figure 1 ). CTX2 and CTX3 displayed a similar spectrum to that of CTX, strongly suggesting that they adopted the native-like fold. For a peptide with a random coil structure, the CD spectrum should contain a positive maximum at around 212 nm and a negative minimum at 195 nm. CTX1 presents this signature ( Figure 5 , open rhombus),
indicating that the disulfide bonds are important for stabilising the structure of CTX.
Thus, we conclude that the overall structure of the analogues CTX2 and CTX3 is comparable to that of CTX but different to that of CTX1. It should be noted that although the CD spectra indicated that CTX2 and CTX3 had similar overall conformations compared to the native peptide, the 1 H 1D spectra of both peptides indicated that there was significant conformational flexibility (Supplementary Figure   1 ). Based on this observation, we postulate that removal of both Cys I-IV and II-VI bonds will have a significant destructive effect on conformation.
Disulfide bond connectivity
To confirm that the correct disulfide bond pairing had formed for CTX2 and CTX3, these peptides were partially reduced to generate a mixture of isoforms with some disulfide bonds reduced and the remainder oxidised. The mixtures were subjected to alkylation with NEM and subsequently analysed using mass spectrometry, identifying the presence of peptides with either two or four NEM-alkylated cysteines. Peptides with a differing number of NEM modifications were separated using RP-HPLC and completely reduced using DTT and further subjected to a second alkylation with IAM. To facilitate their MS/MS characterization, the alkylated peptides were digested with trypsin to obtain smaller peptide fragments. The peptides that were analyzed by MS/MS are shown in Table 1 and Supplementary Figure 2 . MS/MS sequencing of the CTX2 isoform containing two NEM-alkylated cysteines reveled that Cys II and Cys VI were alkylated with NEM, confirming that the disulfide bond Cys II-VI had formed correctly. Similarly, MS/MS analysis of CTX3 containing two NEMalkylated cysteines indicated that Cys I-IV had also formed correctly. For the CTX3 derivative containing four NEM-alkylated and two carbamidomethyl cysteines, the NEM-alkylated cysteines were identified to be Cys I, Cys IV, Cys V, and Cys VIII, which is consistent with a Cys I-IV and Cys V-VIII connectivity, and the carbamidomethyl cysteines were Cys III and Cys VII. We were unable to isolate the CTX2 derivative containing four NEM-alkylated cysteines because it did not produce a defined peak during the partial reduction procedure (Supplementary Figure 3) .
Nonetheless, we concluded that CTX2 formed the correct disulfide bond connectivity based on the obtained MS data and the excellent agreement between the CD spectra of CTX, CTX2 and CTX3 ( Figure 5 ). Thus, sequencing of the differentially alkylated derivatives of CTX2 and CTX3 indicated that the correct disulfide bond connectivity had formed.
Stability of peptides
CTX is a very stable peptide that can resist enzymatic proteolysis in vitro and in vivo [15] . To compare the relative stabilities of the analogues, CTX, CTX1, CTX2 and CTX3 were incubated in human serum (containing proteolytic enzymes), and in PBS at 37°C and monitored over 24 h. As expected, PBS did not have an effect on peptide stability (data not shown). Consistent with a previous study [15] , CTX displayed high stability, with around 80% of intact CTX remaining after 24 h incubation ( Figure   6A ). Compared to CTX, CTX2 and CTX3 degraded rapidly, with less than 15% of the intact peptides remaining after 12 h. Figure 6A shows that CTX1 had the lowest stability of all peptides tested, as it had completely degraded after 3 h.
Biological activity
CTX can inhibit cell migration of HUVECs through a mechanism that may involve multiple pathways [3] . The biological activity of native CTX and its analogues were studied by measuring their ability to inhibit HUVEC migration. Firstly, we confirmed that CTX, CTX1, CTX2 and CTX3 were not toxic to HUVECs; CTX and CTX1
showed no toxic effects up to a tested concentration of 200 µM, whereas CTX2 and Figure 6B) . Surprisingly, CTX1, which is analogous to the completely reduced form of CTX, had inhibitory activity that was similar to the native peptide, suggesting that the three dimensional structure of CTX formed by the disulfide bonds is not required for the inhibitory effect on cell migration.
Discussion
CTX forms a compact tertiary structure containing a highly cross-linked core composed of four disulfide bonds. In this study, we aimed to gain insights into the role of individual disulfide bonds on the structure and function of CTX, which would facilitate the design and development of optimised cancer drug leads based on the CTX scaffold.
Role of disulfide bonds in the structure of chlorotoxin
Our conformational analysis suggested that Cys I-IV and Cys II-VI can be removed without affecting the overall topology of CTX, highlighting the structural similarity between CTX and the α/β family of scorpion peptides. As mentioned in the introduction, the disulfide bonds Cys II-VI, Cys III-VII and Cys V-VIII of CTX are topologically similar to the disulfide bond configuration of the α/β family of scorpion toxins. Deletion of Cys I-IV resulted in a disulfide bond connectivity identical to that of the α/β family, which require only three disulfide bonds to form their native structures. Moreover, deletion of Cys II-VI of CTX, which corresponds to the first disulfide bond in the α/β motif, did not affect the overall structure of CTX. This behaviour has been reported for other α/β toxin family members, namely leiurotoxin I and charybdotoxin, where deletion of the first disulfide bond did not affect the overall structure [24, 25, 31] . In studies on leiurotoxin I and charybdotoxin, deletion of the second or third disulfide bonds was important for folding into a native structure. We observed a similar behaviour for CTX analogues; deletion of either Cys III-VII or Cys V-VIII in CTX, which correspond to the second and third disulfide bonds, respectively, in leiurotoxin I and charybdotoxin, had a significant impact on the ability of the peptides to fold into their native structure.
Analysis of the disulfide bond connectivity of native CTX indicates that it contains a cystine knot motif, with Cys V-VIII being a fourth and additional disulfide bond.
However, the oxidative folding of CTX was significantly affected by the removal of Cys V-VIII. Thus, even though CTX may contain features of the cystine knot family, structurally it is more closely related to the α/β motif family.
Role of disulfide bonds in stability
CTX contains four disulfide bonds, and, as is typical for disulfide-rich peptides [20] , is very stable against chemical and biological degradation both in vivo and in vitro [15] . When discussing the potential of CTX in drug design, its stability is one of the most attractive pharmacological features, as poor stability is a major limitation facing the development of peptides as drugs or drug scaffolds [32] . The high serum stability of CTX may be due to its highly compact fold, which is stabilised by the presence of four disulfide bonds, reducing exposure of its sequence to proteolytic attack. Our finding that CTX1, which contains no disulfide bonds, was rapidly degraded provides evidence to support the idea that a well-defined conformation is important for stability. Interestingly, CTX2 and CTX3 were both less stable than CTX, though they were able to maintain the native-like fold. This might be due to the fact that both lacked one disulfide bond compared to CTX, which could potentially introduce increased conformational flexibility and therefore increased accessibility to enzymatic proteolysis. This is consistent with reports of other disulfide rich peptides, where modification of the disulfide bond conformation affected stability [21, 28] .
Role of disulfide bonds in activity
The biological activity of native CTX and its analogues was tested by measuring their ability to inhibit the migration of HUVECs. As shown in Figure 6B , all peptides were able to inhibit HUVEC migration. In the case of CTX2 and CTX3, the deletion of one disulfide bond does not result in any changes in the ability to inhibit angiogenesis, which was expected because CTX2 and CTX3 adopted a native-like conformation and we initially assumed that the activity of CTX was dependent on its tertiary structure. However, the reduced form, CTX1, which adopted a random coil structure, was also found to inhibit the migration of HUVECs with a similar potency as CTX, suggesting that a well-defined native-like fold is not required for the inhibitory activity and that it is, in fact, the primary structure which is important. It is therefore tempting to speculate that the activity of CTX against cell migration does not involve a specific cell receptor.
Our work contrasts with some aspects of a study on charybdotoxin, which demonstrated that its disulfide bond arrangement is important to maintain activity of the peptide [25] . The observed uncoupling between structure and activity for CTX with respect to cell migration inhibitory activity might not apply to other activities: in nature, the function of CTX is to subdue a target prey or organism and in that role, the disulfide bonds might be vital. On the other hand, our results are consistent with a recent study on a θ-defensin, a three disulfide-bond peptide from leukocytes of rhesus macaques, which showed that its disulfide bonds are not important for its antibacterial activity [28] . From a drug design perspective, it is worth noting that the migration assay was performed in a serum-free environment, i.e., no peptidases were present to degrade the peptides. Therefore, in an in vivo setting, the higher stability of CTX (compared to that of CTX1) would probably translate to higher effective inhibitory activity.
Cyclisation to improve stability
Our study showed that for CTX, three disulfide bonds are sufficient to produce a native-like structure. Cys III-VII and Cys V-VIII are critical for the formation of a folded peptide, whereas Cys I-IV and Cys II-VI are not required for maintaining the overall fold. This is a significant finding because the reduced chemical complexity of a CTX analogue containing only three disulfide bonds, compared to the four-disulfide bond CTX, may be more favourable for large-scale industrial production. However, it is important to note that the deletion of one disulfide bond does significantly affect the stability of the peptide. We postulate that this reduced stability might be reversed through backbone cyclisation, based on the fact that cyclisation can reduce the accessibility of terminal amino acids to serum peptidases and enhance conformational rigidity [33, 34] . Although cyclisation might potentially complicate production of CTX analogues, modern chemical and biochemical approaches (e.g. enzymemediated methods [35, 36] facilitate efficient synthesis of cyclic peptide derivatives.
Backbone cyclisation has been applied to the native CTX to improve serum stability by around 20%, [15] as well as other disulfide-rich peptides [23, 37, 38] . In some cases, cyclisation can also improve the potency of the peptide; for example, cyclisation of gomesin, an 18-residue cysteine-rich peptide from the spider Acanthoscurria gomesiana, improved its toxicity against cancer cells [23] as well as its antimalarial activity [23] .
CTX as a scaffold for drug design
Primary structure comparison of CTX with other small scorpion toxins containing the α/β structural motif indicates that the only conserved amino acids are the six cysteines that form the motif [25] . The α/β motif can tolerate multiple sequence combinations, indicating that we should be able to modify the sequences between the cysteines of the α/β motif without losing the overall structure. Thus, CTX is potentially a valuable scaffold for incorporation of biologically-active peptide epitopes, such as those with antitumor or anti-angiogenesis activity into its sequence using an approach called molecular grafting to combine the favourable pharmacological features of CTX (i.e. stability and binding specificity to cancer cells) with the activity of the peptide epitope. This approach has been successfully used to design stable disulfide-rich peptides that have potent activity in animal models of chronic diseases [19, 27, 39, 40] .
In conclusion, our study has shown that for CTX, three disulfide bonds are necessary and sufficient to produce a native-like structure. The bonds formed by Cys III-VII and Cys V-VIII are essential for correct peptide folding; whereas, those formed by Cys I-IV and Cys II-VI can be removed without affecting the structure, though their removal significantly alters the stability of the peptide. Finally, we have shown that the disulfide bonds are not necessary for CTX to exert its inhibitory action on cell migration.
Future perspective
In recent years there has been increased interest in the development of peptides as therapeutics. In general, this is because peptides offer better selectivity and potency compared to small molecules, as well as potentially fewer side effects [20] . Despite these advantages, peptides still face the significant challenges of poor stability and bioavailability. CTX could be an excellent scaffold peptide to try to overcome these challenges, as it is highly stable. Our data suggest that significant changes to the sequence of CTX, without affecting the overall conformation, might be possible.
CTX has a natural ability to preferentially bind to cancer cells and therefore has significant potential in cancer drug development.
Executive summary
Role of disulfide bonds in the structure of chlorotoxin
Two specific pairings are important to form the native-like structure of CTX. The cystine pairs Cys I-IV and Cys II-VI can be removed without significantly affecting the structure of CTX. However, cystine pairs Cys III-VII and Cys V-VIII are important for forming the native structure.
Role of disulfide bonds in stability
Although CTX is a very stable peptide, it needs all four disulfide bonds to prevent it from being susceptible to protease degradation. When a single disulfide bond is lacking, stability is reduced.
Role of disulfide bond in activity
The ability of CTX to inhibit HUVEC migration does not depend on the native disulfide bond connectivity stabilising the tertiary structure because the reduced form is able to inhibit HUVEC migration with a similar potency to native CTX. The disulfide bond connectivities are shown as solid black lines and the cysteine residues are labelled using Roman numerals from I to VIII. The 'outlier' disulfide connectivity that differs between the two molecules is shown on the CTX sequence.
B. Sequence alignment of CTX with kalata B1, which comprises a cystine knot motif.
The disulfide bond connectives are shown as solid black lines and the cysteine residues are labelled using Roman numerals from I to VIII. The 'outlier' disulfide connectivity that differs between the two molecules is shown on the CTX sequence.
The cyclic backbone of kalata B1 is shown at the bottom of the sequence by a dashed black line that joins both ends of the molecule. The data is shown as mean and standard deviation of triplicate measurements from a combination of three independent experiments. Statistical analyses using one way ANOVA showed that the activities of CTX1, CTX2 and CTX3 were not significantly different to that of the native parent peptide. However when compared to the positive control (VEGF), these analogues were significant different with p-value < 0.05. 
